Please login to the form below

Not currently logged in
Email:
Password:

Gamida Cell strengthens leadership team

Appoints Josh Hamermesh and Paul Nee

Josh HamermeshCellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh.

Hamermesh (pictured right), who joins from Locust Walk Partners where he served as senior vice president, will lead the business operations and corporate development strategies for the company.

He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.

Paul NeeAlongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.

Julian Adams, chairman and chief executive officer of Gamida Cell, said: “We are pleased to welcome Josh and Paul to the Gamida Cell leadership team.

“Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic diseases.”

4th May 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...